Groundbreaking Drug Launches
Zilganersen (ION1166998)
Mechanism of Action: Glial fibrillary acidic protein expression inhibitors; RNA interference Drug class: Antisense oligonucleotides Originator: Ionis Pharmaceuticals Indication: Alexander disease
Expected approval: Q1 2026
Trial: ION373-CS1
Alexander disease
Alexander disease is a rare, progressive genetic disorder of the nervous system and a type of leukodystrophy. It is caused by mutations in the GFAP gene, leading to abnormal protein buildup, damage to myelin, and neurological problems such as developmental delays, seizures, and muscle stiffness. The condition can appear from infancy through adulthood, and while there is currently no cure, treatment focuses on managing symptoms.
Treatment challenges Treatment of Alexander disease is challenging due to its extreme rarity, absence of curative therapies, and progressive course, which necessitate complex, multidisciplinary care. Management focuses on controlling severe symptoms such as seizures, spasticity, feeding and breathing difficulties, and developmental delays, while clinicians and families face limited clinical data and the high costs of emerging gene-based therapies. For researchers, translating encouraging results from animal models—such as antisense oligonucleotides—into effective human treatments remains difficult because of differences in human brain biology and disease complexity.
Why is Zilganersen poised to make an impact in 2026?
Ionis Pharmaceuticals is preparing to launch its first wholly-owned neurology medicine, Zilganersen, in 2026. Developed for Alexander disease (AxD)—a rare, progressive, and often fatal neurological disorder with no approved treatments—Zilganersen represents a first-in-class, disease-modifying therapy. The company plans to submit a New Drug Application (NDA) in early 2026 and initiate an Expanded Access Program (EAP) in the U.S. Ionis has also received Breakthrough Therapy designation for Zilganersen in AxD, underscoring its potential as a transformative treatment.
Zilganersen is projected to achieve strong U.S. peak sales (approximately $295 million), driven by high adoption within the eligible patient population.
Regulatory milestones for Zilganersen
Registrational Trial
The FDA has granted Breakthrough Therapy designation to Zilganersen for treating Alexander disease, based on promising topline results from its pivotal study.
ION373-CS1:
A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients With Alexander Disease (NCT04849741).
"The ION373-CS1 trial marks the first time an investigational therapy has shown a positive disease-modifying effect in Alexander disease"